February 25, 2020 09:11 AM EST Jason Mast R&DCoronavirus

Tuesday, February 25, 2020

Study enrolling hospitalized adults with COVID-19 in Nebraska.

 https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins 

LEFT

RIGHT

8 OF 10

READ ALL TODAY'S ISSUE IN FULL

 26-02-2020 

 https://www.thepharmaletter.com/article/nih-starts-testing-gilead-s-remdesivir-as-treatment-for-covid-19 

Posted onFebruary 23, 2020AuthorIan M Mackay, PhD (EIC)107 Comments

by Jody Lanard and Peter M. Sandman

 https://virologydownunder.com/past-time-to-tell-the-public-it-will-probably-go-pandemic-and-we-should-all-prepare-now/ 

 China / Society

• Some people are struggling to get back to their workplaces while those who can face quarantine and financial uncertainties
• Businesses are also feeling the squeeze as they try to absorb the cost of extra protective equipment and measures.

Guo Rui

Published: 8:00am, 26 Feb, 2020

 https://www.scmp.com/news/china/society/article/3052329/big-unknowns-millions-they-return-work-chinas-economic 

 Feb 26, 2020 06:47 AMSOCIETY & CULTURE

By Li Liuqian, Huang Shulun and Han Wei 

 https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19-patients-in-guangdong-tested-positive-again-101520415.html 

Wed February 26, 2020 7:00 AM|GlobeNewswire|About: TNXP

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) 

 https://www.tonixpharma.com/ 

 https://www.tonixpharma.com/pipeline/overview 

 https://southernresearch.org/ 

FEBRUARY 26, 2020 | BY JERRY UNDERWOOD | DRUG DEVELOPME 

 https://southernresearch.org/news/southern-research-tonix-team-to-develop-potential-vaccine-against-new-coronavirus/ 

 https://seekingalpha.com/symbol/TNXP 

 Feb 26, 2020 10:24 PMSOCIETY & CULTURE

 https://www.caixinglobal.com/2020-02-26/coronavirus-wednesday-update-switzerland-austria-brazil-sound-alarm-on-first-cases-101520678.html 

 http://www.china.org.cn/china/2020-02/26/content_75745874.htm 

Source: Xinhua| 2020-02-25 19:05:41|Editor: huaxia 

 http://www.xinhuanet.com/english/2020-02/25/c_138817801.htm 

Despite China's best efforts the coronavirus outbreak has spread rapidly around the world. Many cities in Hubei province remain in lockdown and an increasing number of international flights to China have been suspended.

BY SCMP GRAPHICS UPDATED FEBRUARY 18, 2020

 https://multimedia.scmp.com/infographics/news/china/article/3047038/wuhan-virus/index.html?src=article-launcher 

 Article Navigation >  China CDC Weekly  > 2020, 2(8): 113-122

• The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team

 http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51 

By AYA BATRAWYan hour ago
 DUBAI, United Arab Emirates (AP) — A staggering 50 people have died in the Iranian city of Qom from the new coronavirus this month, a lawmaker was quoted as saying on Monday, even as the Health Ministry insisted only 12 deaths have been recorded to date in the country. 

 The lawmaker said the 50 deaths date as far back as Feb. 13. Iran first officially reported cases of the virus and its first deaths in Qom on Feb. 19. 

 Feb 24, 2020 08:22 PMSOCIETY & CULTURE

 https://www.caixinglobal.com/2020-02-24/coronavirus-monday-update-china-logs-150-new-deaths-south-korea-italy-case-counts-spiral-101519489.html 

 http://china.caixin.com/2020-02-24/101519629.html 

• Iran’s health minister says the infections are believed to be linked to a merchant who bypassed travel restrictions by making indirect flights to China
• Qom, south of the capital Tehran, has been identified as the centre of contagion, but authorities have warned it is possible the virus is present in all cities

John Power

Published: 8:17pm, 24 Feb, 2020

 https://www.scmp.com/week-asia/explained/article/3052143/coronavirus-how-irans-death-toll-came-be-highest-behind-only 

Fact Checked

Share on PinterestMultiple companies are working on a vaccine to fight the new coronavirus. Getty Images

• Several groups are working on a vaccine for the new coronavirus, but there’s no guarantee that it will be ready before the end of the current outbreak.
• One group says they may have an experimental vaccine ready for initial testing in just a month.
• But experts caution this expedited timeline doesn’t always allow for careful evaluation of the safety and effectiveness of the vaccines.

 https://www.healthline.com/health-news/how-long-will-it-take-to-develop-vaccine-for-coronavirus 

Richard StainesFebruary 21, 2020

A Chinese research foundation has awarded $2.1m to four teams from Columbia University to identify antiviral drugs that work against the COVID-19 coronavirus – including a project investigating whether compounds based on Gilead’s hepatitis C drug Sovaldi could be used against the outbreak.

The funding was awarded by the Jack Ma Foundation, based in Hangzhou City, in China’s Zhejiang Province.

 https://pharmaphorum.com/news/could-gileads-sovaldi-be-the-answer-to-coronavirus/ 

 SOVALDI is sofosbuvir 

 https://www.sovaldi.com/ 

Early trial results from an unapproved Gilead drug, remdesivir, are expected in the next three weeks.

Results are also expected from a trial combining AbbVie’s HIV drugs lopinavir and ritonavir.

 KALETRA® (lopinavir/ritonavir) 

 https://www.kaletra.com/ 

By Chris Lau, InvestorPlace Contributor Feb 6, 2020, 10:50 am EST 

 https://investorplace.com/2020/02/7-biotech-stocks-to-buy-that-could-beat-thee companies may save the day-coronavirus/ 

 February 25, 2020 09:11 AM EST Jason Mast R&DCoronavirus

 https://endpts.com/first-us-covid-19-trials-set-to-get-underway-in-nebraska-and-washington-backed-by-nih/ 

Special

February 14, 2020, by Michael Every et al.

 https://economics.rabobank.com/publications/2020/february/coronavirus-outbreak-of-uncertainty/ 

NIAID Now | February 19, 2020

 https://www.niaid.nih.gov/news-events/atomic-structure-novel-coronavirus-protein 

CDC is closely monitoring the novel coronavirus outbreak.

Learn More

  Coronavirus Disease 2019 (COVID-19) 

 https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html 

Mon February 24, 2020 6:04 PM|Business Wire|About: AZN, MRK, MRNA

mRNA-1273 delivered from Company’s cGMP facility in 42 days from sequence selection

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (MRNA)

NIAID Now | February 19, 2020

 https://www.niaid.nih.gov/news-events/atomic-structure-novel-coronavirus-protein 

August 19, 2019 at 4:01 PM EDTPDF Version

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 19, 2019-- Moderna, Inc., (Nasdaq: MRNA)

 https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-zika-vaccine-mrna 

 https://www.modernatx.com/ 

 https://investors.modernatx.com/news-releases/news-release-details/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273 

 https://www.businesswire.com/news/home/20200224005955/en/ 

 https://seekingalpha.com/symbol/MRNA 

Gilead Sciences' antiviral remdesivir may be effective against the coronavirus, the World Health Organization says.TONY OWUSUUPDATED:FEB 24, 2020 10:05 AM ESTORIGINAL:FEB 24, 2020 

 https://www.thestreet.com/investing/gilead-remdesivir-coronavirus 

 https://www.bloomberg.com/news/articles/2020-02-24/gilead-surges-after-who-comments-on-coronavirus-drug-testing?utm_medium=social&utm_content=business&utm_campaign=socialflow-organic&utm_source=twitter&cmpid=socialflow-twitter-business 

Feb. 24, 2020 9:57 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Liz Kiesche, SA News Editor  

 https://seekingalpha.com/news/3544811-gilead-gains-4_8-who-sees-potential-in-antiviral-drug 

 https://www.gilead.com/science-and-medicine/pipeline 

By Paul R. La Monica, CNN Business

Updated 6:04 AM ET, Tue February 25, 2020 

 https://www.cnn.com/2020/02/24/investing/gilead-sciences-coronavirus-who-remdesivir/index.html 

 February 25, 2020 09:11 AM EST Jason Mast R&DCoronavirus

 https://endpts.com/first-us-covid-19-trials-set-to-get-underway-in-nebraska-and-washington-backed-by-nih/ 

 https://clinicaltrials.gov/ct2/show/NCT04280705?cond=covid-19&cntry=US&draw=2&rank=1 

 Feb 21, 2020 06:29 AMSOCIETY & CULTURE

Thursday, Feb. 20 11:45 p.m.

Recent research again linked an endangered mammal, the pangolin, to the novel coronavirus that has sickened more than 75,000 people worldwide, as scientists strive to determine the intermediate host of the deadly virus.

 https://www.caixinglobal.com/2020-02-21/coronavirus-thursday-update-japan-reports-two-deaths-among-diamond-princess-cruise-ship-passengers-101517958.html 

 http://www.caixin.com/2020-02-20/101518165.html 

By SHANNON PALUS FEB 19, 2020 4:52 PM 

 https://slate.com/technology/2020/02/coronavirus-origin-pangolins-trafficking-endangered.html 

• Chinese respiratory expert warns numbers could rise again as tests show people who have recovered may still be infectious
• Globally there have been 75,773 confirmed cases and 2,129 deaths

Robert Delaney

Published: 7:21am, 21 Feb, 2020

 https://www.scmp.com/news/china/society/article/3051688/coronavirus-115-new-deaths-confirmed-hubei-officials-report-411 

By Wang Keju | chinadaily.com.cn | Updated: 2020-02-20 11:47 

 https://www.chinadaily.com.cn/a/202002/20/WS5e4e0160a310128217278fb1.html 

• A month has passed since China locked down millions of people in Wuhan and other cities in Hubei at the heart of the epidemic
• In the first part of a series, the Post looks at how the race to find a vaccine may be different than for other coronaviruses

Josephine Ma and Simone McCarthy

Published: 6:15am, 22 Feb, 2020

 https://www.scmp.com/news/china/science/article/3051853/there-was-no-vaccine-sars-or-mers-will-there-be-one-new 

 Feb 22, 2020 10:06 PMSOCIETY & CULTURE

 https://www.caixinglobal.com/2020-02-22/coronavirus-saturday-update-first-european-dies-in-italy-chinas-official-case-count-reaches-76392-101519032.html 

• Antiviral remdesivir is being trialled as a treatment for the novel coronavirus in 10 hospitals in Wuhan
• Researchers have recruited more than 230 patients for the trials so far, short of the 760 targeted

Coco Feng in Beijing

Published: 7:30pm, 21 Feb, 2020

 https://www.scmp.com/tech/science-research/article/3051820/chinese-trials-gileads-antiviral-drug-treat-coronavirus-still 

 Clinical trials of an experimental antiviral drug said to “

show promise

” in treating the 

deadly coronavirus

are still far from fulfilling patient recruitment targets more than two weeks in, raising questions about whether they can be completed within previously projected timelines. 

• Preliminary results from two clinical trials testing potential treatments for the COVID-19 coronavirus are expected in three weeks, WHO says.
• One trial combines HIV drugs Lopinavir and Ritonavir, while the other is testing U.S.-based biotech Gilead Sciences’ antiviral Remdesivir.

 https://www.cnbc.com/2020/02/20/early-trial-results-for-potential-coronavirus-treatments-expected-in-three-weeks-who-says.html 

 https://www.cnbc.com/quotes/?symbol=GILD 

Feb. 20, 2020 10:20 AM ET

The political and socio-economic environment in America, is both depressing and disconcerting.

The hostility increases towards everyone connected with the biotech/drug industry during this highly politically charged season.

Politicos still see little to no value in biotech companies and continue to vilify them.

There continues to be much encouraging news and positive clinical tests in the biotech world, including on the coronavirus situation, for the first 2 months of 2020.

 https://seekingalpha.com/instablog/5205071-danwatson888/5411014-biotecheart-see-light 

 https://seekingbiotechalpha.com/biotecheart 

www.biotecheart.com

 Biological Sciences

RESEARCH ARTICLE

View ORCID ProfileEmmie de Wit, Friederike Feldmann, Jacqueline Cronin, Robert Jordan, Atsushi Okumura, Tina Thomas, Dana Scott, Tomas Cihlar, and Heinz FeldmannPNAS first published February 13, 2020 https://doi.org/10.1073/pnas.1922083117

1. Edited by Michael B. A. Oldstone, Scripps Research Institute, La Jolla, CA, and approved February 7, 2020 (received for review December 16, 2019)

 Remdesivir reduced the severity of disease, virus replication, and damage to the lungs when administered either before or after animals were infected with MERS-CoV. Our data show that remdesivir is a promising antiviral treatment against MERS that could be considered for implementation in clinical trials. It may also have utility for related coronaviruses such as the novel coronavirus 2019-nCoV emerging from Wuhan, China. 

by Angus Liu | Feb 12, 2020 10:28am 

 https://www.fiercepharma.com/pharma-asia/chinese-firm-copies-gilead-s-remdesivir-most-promising-drug-against-new-coronavirus 

 BrightGene Bio-Medical Technology Co.,Ltd. 

 http://www.bright-gene.com/en/product_category.php 

 https://www.gilead.com/science-and-medicine/pipeline 

 BY Alvin PowellHarvard Staff Writer

DATEFebruary 11, 2020

 In China, the number of confirmed cases of the coronavirus reached 42,700 on Feb. 11, according to the World Health Organization. To accommodate the growing number, an exhibition center was turned into a temporary hospital in Wuhan. 

10 February 2020 - Imperial College London‌

 https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus/ 

by Kate Wighton, Dr Sabine L. van Elsland11 February 2020

 https://www.imperial.ac.uk/news/195217/coronavirus-fatality-rate-estimated-imperial-scientists/ 

Steven Sanche, Yen Ting Lin, Chonggang Xu, Ethan Romero-Severson, Nick Hengartner,  View ORCID ProfileRuian Kedoi: https://doi.org/10.1101/2020.02.07.20021154 

 https://www.medrxiv.org/content/10.1101/2020.02.07.20021154v1 

 Feb 18, 2020 08:10 PMSOCIETY & CULTURE

By Dave Yin and Chen Lixiong 

 https://www.caixinglobal.com/2020-02-18/evidence-mounts-of-japans-mishandling-of-coronavirus-epidemic-101517257.htm 

Tue February 18, 2020 5:42 AM|PR Newswire|About: WXXWY

SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- WuXi Biologics (WXXWY)

 https://seekingalpha.com/pr/17781014-wuxi-biologics-subsidiary-wuxi-vaccines-signed-long-term-vaccine-manufacturing-contract 

 Economy /  China Economy

• Most Chinese companies will resume operations this week, but the coronavirus outbreak is still raging and it’s far from business as usual
• Transport restrictions, supply chain disruptions and new workplace rules to minimise the risk of transmission all cloud the short-term economic outlook

Topic |   Coronavirus outbreak

Karen Yeung andSidney Leng

Published: 6:00am, 13 Feb, 2020

 To work or not to work – that is proving a crucial question for Chinese officials, companies and employees as the world’s second largest economy struggles to balance the risk of the deadly coronavirus with the need to resume business. 

 HEALTH

By SHARON BEGLEY @sxbegle

FEBRUARY 4, 2020

 https://www.statnews.com/2020/02/04/two-scenarios-if-new-coronavirus-isnt-contained/ 

National Health Commission of the
People's Republic of China

中华人民共和国国家卫生健康委员会 

Updated: 2020-02-12

|en.nhc.gov.cn

 http://en.nhc.gov.cn/2020-02/12/c_76463.htm 

 China / Society

• Majority of new cases and deaths have been reported from the province at the heart of the outbreak
• China postpones annual parliamentary meeting scheduled for early March

Robert Delaney

Published: 7:02am, 18 Feb, 2020

 https://www.scmp.com/news/china/society/article/3051063/coronavirus-chinas-hubei-province-records-1807-new-cases-93 

The View by Mark Clifford

• Lessons that should have been learned after the harrowing Sars experience were not: diseases like Covid-19 will happen from time to time in a hyper-connected world, and the trust and transparency that will fortify a society’s response to such a crisis is lacking

Mark Clifford

Published: 3:00am, 19 Feb, 2020

 https://www.scmp.com/comment/opinion/article/3051079/coronavirus-was-no-black-swan-hong-kong-and-china-just-werent-ready 

 Actualité  Société

AFPPublié le 14/02/2020 à 14:33 | AFP 

 https://www.lepoint.fr/societe/nouveau-coronavirus-le-patient-de-bordeaux-a-recu-du-remdesivir-14-02-2020-2362739_23.php 

 Feb 16, 2020 11:16 AM

By Jia Tianqiong, Di Ning, Lu Yutong and Flynn Murphy 

 https://www.caixinglobal.com/2020-02-16/second-batch-of-experimental-gilead-coronavirus-drug-arrives-in-wuhan-101516104.html 

By Liu Kun in Wuhan and Zhao Lei in Beijing | chinadaily.com.cn | Updated: 2020-02-07 23:21 

 https://www.chinadaily.com.cn/a/202002/07/WS5e3d8068a310128217275e9d.html 

By Wang Xiaoyu  | chinadaily.com.cn | Updated: 2020-02-15 17:33 

 https://www.chinadaily.com.cn/a/202002/15/WS5e47bad4a310128217277c96.html 

 three drugs that hold great promise - chloroquine diphosphate, favipiravir and remdesivir - are undergoing human trials in the country. 

 Home / China / The fight against novel coronavirus

chinadaily.com.cn | Updated: 2020-02-16 06:30 

 https://www.chinadaily.com.cn/a/202002/16/WS5e2a95d9a310128217273202.html 

• Hubei province’s new Communist Party chief calls for less bureaucracy as number of new infections rises again
• World Health Organisation says it is impossible to predict the future path of the epidemic, which has spread to at least 25 other countries

Cissy Zhou, Gigi Choy and Wendy Wu

Published: 7:27am, 17 Feb, 2020

By Hodan Osman Abdi | cgtn | Updated: 2020-02-17 11:24 

 https://global.chinadaily.com.cn/a/202002/17/WS5e4a0780a3101282172780e9.html 

11 February 2020 

 Feb 12, 2020 09:21 PMDAILY CHART

By Tang Ziyi, Lin Jinbing, Ye Xueming and Wang Xintong 

 https://www.caixinglobal.com/2020-02-12/charts-of-the-day-how-deadly-is-new-coronavirus-101514627.html 

Audrey Jiajia Li

• A reluctant hero, the doctor who was reprimanded for warning about the coronavirus has, in death, become a lightning rod for public unhappiness with the government’s tight control of information

Audrey Jiajia Li

Published: 9:00am, 12 Feb, 2020

 https://www.scmp.com/comment/opinion/article/3049910/coronavirus-crisis-how-death-li-wenliang-doctor-and-ordinary 

 China / Politics

• Public fury is growing, with calls for more freedom of speech, but observers don’t expect any dramatic changes
• Xi Jinping has been mostly absent from view, as heads start to roll in Hubei province

Jun Mai

Published: 6:00pm, 13 Feb, 2020

 https://www.scmp.com/news/china/politics/article/3050331/beijing-battles-crisis-chernobyl-proportions-coronavirus 

Andy Xie

• An all-powerful government means a swift and effective quarantine but the same hierarchical system caused critical delays in containing the coronavirus
• Likewise, the China model, so effective when the economy was nascent, has outlived its usefulness in a country now trying to beat the middle-income trap

Andy Xie

Published: 9:00am, 31 Jan, 2020

 https://www.scmp.com/comment/opinion/article/3048084/how-coronavirus-crisis-exposing-ills-china-model 

Wed February 12, 2020 8:30 AM|GlobeNewswire|About: VIR 

 https://www.vir.bio/ 

 https://seekingalpha.com/symbol/VIR 

The coronavirus which was first reported in Wuhan late last year has quickly spread around the world. The Chinese authorities have locked down many cities in China's Hubei province, and some international flights to China have been suspended.

BY SCMP GRAPHICS UPDATED FEBRUARY 11, 2020

 https://multimedia.scmp.com/infographics/news/china/article/3047038/wuhan-virus/index.html 

 Feb 13, 2020 12:53 PMSOCIETY & CULTURE

 https://www.caixinglobal.com/2020-02-13/coronavirus-latest-since-feb-1-confirmed-cases-14380-in-china-canada-starts-limited-evacuation-but-no-travel-ban-101510591.html 

 FEBRUARY 13, 2020 / 12:24 AM / UPDATED AN HOUR AGO

 (Reuters) - Here are the latest developments around the coronavirus outbreak: 

 https://www.reuters.com/article/us-china-health-latest-idUSKBN2070F2?taid=5e45317781f80800015293c5&utm_campaign=trueAnthem:+Trending+Content&utm_medium=trueAnthem&utm_source=twitter 

Foster City, Calif., January 31, 2020 

 Remdesivir has demonstrated in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are coronaviruses that are structurally similar to 2019-nCoV. 

 https://www.wsj.com/articles/gilead-sciences-scrambles-to-supply-experimental-coronavirus-drug-11581522704 

 https://time.com/5782633/covid-19-drug-remdesivir-china/ 

 BrightGene Bio-Medical Technology Co. Ltd. (Suzhou, China)  

 http://www.bright-gene.com/en/ 

by Angus Liu | Feb 12, 2020 10:28am 

 https://www.fiercepharma.com/pharma-asia/chinese-firm-copies-gilead-s-remdesivir-most-promising-drug-against-new-coronavirus 

COMPANY INFO 

 https://www.bloomberg.com/quote/688166:CH 

• Published: 04 February 2020

• Manli Wang, 
• Ruiyuan Cao, 
• Leike Zhang, 
• Xinglou Yang, 
• Jia Liu, 
• Mingyue Xu, 
• Zhengli Shi, 
• Zhihong Hu, 
• Wu Zhong & 
• Gengfu Xiao 

Cell Research (2020)

 https://www.nature.com/articles/s41422-020-0282-0 

Tue February 11, 2020 4:30 PM|PR Newswire|About: JNJPR Newswire

NEW BRUNSWICK, N.J., Feb. 11, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ)

Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat

Initiating Vaccine Development and Providing Supplies of Antiviral Medicines to China for Investigational Use

 https://www.jnj.com/johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat 

 Johnson & Johnson Announces Collaboration with U.S. Department of Health and Human Services to Fight InfluenzaJanssen and Biomedical Advanced Research and Development Authority (BARDA) join forces to accelerate new therapies and vaccines to protect communities against the threat of a pandemic

NEW BRUNSWICK, N.J., – September 15, 2017 – Johnson & Johnson (NYSE: JNJ)

 https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-us-department-of-health-and-human-services-to-fight-influenza 

 https://www.jnj.com/johnson-johnson-announces-donation-of-up-to-500-000-regimens-of-janssens-investigational-ebola-vaccine-to-support-outbreak-response-in-democratic-republic-of-the-congo-drc 

 https://www.jnj.com/coronavirus 

The coronavirus has made headlines as it has spread from China to other parts of the world. To help stop the global outbreak in its tracks, Johnson & Johnson is already hard at work on a potential preventive vaccine.By Johnson & JohnsonJanuary 28, 2020 

 https://www.jnj.com/latest-news/what-you-need-to-know-about-coronavirus-and-a-potential-johnson-johnson-vaccine 

 https://www.janssen.com/ 

 https://www.jnj.com/innovation 

By Liu Zhihua | China Daily | Updated: 2020-02-05 09:07 

 http://www.chinadaily.com.cn/a/202002/05/WS5e3a156ca310128217274f36.html 

Source: Xinhua| 2020-02-04 23:47:08|Editor: Mu Xuequan 

 http://www.xinhuanet.com/english/2020-02/04/c_138755837.htm 

 Prognosis

By Robert LangrethFebruary 4, 2020, 3:44 PM EST 

 https://www.bloomberg.com/news/articles/2020-02-04/trials-of-gilead-coronavirus-drug-in-china-could-start-next-week 

 Remdesivir is being rushed into trials for the new virus because it previously showed promise in laboratory tests against SARS, a virus similar to the current coronavirus. It’s already been used on the first U.S. coronavirus patient in Washington state, who improved after getting the drug, as well as a handful of other coronavirus patients in the West. 

Bloomberg NewsFebruary 5, 2020, 12:00 AM EST Updated on February 5, 2020, 6:47 AM EST

• Wuhan’s virology institute has applied for remdesivir’s patent
• Gilead said human trials on the drug have begun in China

 https://www.bloomberg.com/news/articles/2020-02-05/china-is-trying-to-patent-gilead-s-experimental-coronavirus-drug 

ISSN 1748-7838 (online) 

• Published: 04 February 2020

 https://www.nature.com/articles/s41422-020-0282-0 

By ZHANG ZHIHAO | China Daily | Updated: 2020-02-06 11:15

Clinical trials begin for remdesivir, which has shown promise in studies

 https://www.chinadaily.com.cn/a/202002/06/WS5e3b84d5a310128217275700.html 

 China / Society

• National Health Commission admits Wuhan lacked intensive care facilities at start of the outbreak, but more beds and staff have now been provided
• And an epidemiologist says preliminary tests have shown two drugs, Arbidol and Darunavir, could effectively inhibit replication of the new strain

William Zheng andMimi Lau

Published: 11:46pm, 4 Feb, 2020

 https://www.scmp.com/news/china/society/article/3048993/chinese-officials-say-priority-stop-mild-coronavirus-cases 

 Arbidol, commonly available as Umifenovir, is a potent antiviral used to treat and prevent influenza, while Darunavir is used to treat and prevent HIV/Aids. 

 https://www.ijidonline.com/article/S1201-9712(18)34836-7/fulltext 

 PREZISTA® (darunavir) is a prescription HIV-1 (Human Immunodeficiency Virus type-1) medicine used with NORVIR® (ritonavir) and other antiretroviral medicines to treat HIV-1 infection in adults. HIV is the virus that causes AIDS (Acquired Immune Deficiency Syndrome). 

 https://www.prezista.com/ 

PREZISTA® (darunavir) is a prescription HIV‑1 (Human Immunodeficiency Virus type‑1) medicine used with NORVIR® (ritonavir) and other antiretroviral medicines to treat HIV-1 infection in adults. HIV is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).

PREZISTA® should not be used in children under 3 years of age.

When used with other antiretroviral medicines to treat HIV‑1 infection, PREZISTA® may help:

• reduce the amount of HIV-1 in your blood. This is called "viral load."
• increase the number of CD4+ (T) cells in your blood that help fight off other infections.

PREZISTA® is always taken with and at the same time as NORVIR® (ritonavir) in combination with other HIV‑1 medicines for the treatment of HIV‑1 infection in adults. PREZISTA® should also be taken with food. 

 https://www.janssencarepath.com/patient/prezista/cost-support 

NORVIR® (ritonavir) tablets and oral solution are prescription medicines each used with other antiviral medicines to treat people with human immunodeficiency virus (HIV-1) infection.

NORVIR® (ritonavir) oral powder is a prescription medicine that is used with other antiviral medicines to treat children with HIV-1 infection.

HIV-1 is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).

 https://www.norvir.com/?cid=ppc_ppd_norvir_ggl_br_0017 

 https://www.scmp.com/business/article/3049227/who-owns-magic-cure-chinas-move-patent-gileads-experimental-drug-could  

 BEIJING (BLOOMBERG) - Chinese researchers have applied for a local patent on an experimental Gilead Sciences drug that they believe might fight the novel coronavirus. 

 https://www.straitstimes.com/asia/east-asia/coronavirus-china-wants-to-patent-gileads-experimental-wuhan-virus-drug?utm_medium=Social&utm_campaign=STFB&utm_source=Facebook#Echobox=1580898360 

 https://www.straitstimes.com/wuhan-virus-outbreak 

 FEBRUARY 5, 2020 / 2:21 AM / UPDATED 11 HOURS AGO

Zhang Yan, David Stanway

BEIJING/SHANGHAI (Reuters)

 “Even if the Wuhan Institute’s application gets authorized, the role is very limited because Gilead still owns the fundamental patent of the drug,” said Zhao Youbin, a Shanghai-based intellectual property counsel at Purplevine IP Service Co. 

 https://www.reuters.com/article/us-china-health-patent-idUSKBN1ZZ0RL 

Potential Indication: Ebola Virus Infection

PHASE 2
https://www.gilead.com/science-and-medicine/pipeline 

 Feb 06, 2020 03:35 AMBUSINESS & TECH

 https://www.caixinglobal.com/2020-02-06/china-wants-to-patent-gileads-experimental-coronavirus-drug-101512006.html 

• Institute of Virology in Wuhan, the epicentre of the global coronavirus outbreak, filed a patent for Gilead’s remdesivir antiviral drug on January 21
• In a statement to the Post, California-based Gilead said it applied for a global patent in 2016, including in China, for using the drug to treat all coronavirus-linked illnesses

Eric Ng

Published: 8:00am, 6 Feb, 2020

 “We are aware of reports of the Wuhan Institute for Virology’s patent application,” said Sonia Choi, Gilead’s vice president of public affairs in a telephone interview with South China Morning Post. “Our focus at this time is on rapidly determining the potential for remdesivir as a treatment for [the novel coronavirus] and accelerating manufacturing in anticipation of potential future supply needs.” 

 “In theory, a patent owner may be able to use its patent to stop other companies from manufacturing, importing or selling that drug in China,” he said. “But a patent cannot stop doctors from prescribing the drug to treat a patient.” 

 https://www.scmp.com/business/article/3049227/who-owns-magic-cure-chinas-move-patent-gileads-experimental-drug-could 

 Feb 06, 2020 07:40 AMSOCIETY & CULTURE

By Xiao Hui 

 Translated By Sun Huixia and Dave Yin 

 https://www.caixinglobal.com/2020-02-06/reporters-notebook-we-interview-front-line-coronavirus-doctor-101512020.html 

 Feb 12, 2020 03:36 AMSOCIETY & CULTURE

 https://www.caixinglobal.com/2020-02-12/coronavirus-latest-since-feb-1-confirmed-cases-14380-in-china-canada-starts-limited-evacuation-but-no-travel-ban-101510591.html 

February 10, 2020 at 5:11 PM ESTPDF Version

Phase 2 CMV vaccine dose-confirmation study more than sixty percent enrolled

mRNA-1189 to prevent infectious mononucleosis and Epstein-Barr virus (EBV) infection

mRNA-1345 to prevent respiratory syncytial virus (RSV) disease in young children, with the intent to combine with mRNA-1653 to create a pediatric respiratory vaccine against RSV, hMPV and PIV3

mRNA-1273 to prevent novel coronavirus (2019-nCoV) disease, in collaboration with the National Institutes of Health; physical manufacturing of first batch complete, awaiting analytical testing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2020-- Moderna, Inc. (Nasdaq: MRNA)

 https://www.businesswire.com/news/home/20200210005823/en/Moderna-Announces-Progress-Prophylactic-Vaccines-Modality-CMV 

 https://www.modernatx.com/pipeline/modernas-mrna-clinical-trials-cmv-mma-zika-several-types-cancer-and-other-diseases 

 Feb 11, 2020 06:05 AMSOCIETY & CULTURE

By Liu Denghui and Denise Jia 

 https://www.caixinglobal.com/2020-02-11/coronavirus-study-finds-incubation-period-of-up-to-24-days-101513859.html 

 https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v1.full.pdf 

 China / Society

• New deaths hit a daily record for Hubei – epicentre of the epidemic – and for mainland China as a whole
• Chinese authorities have partially locked down more than 80 cities in nearly 20 provinces since the epidemic began

Cissy Zhou

Published: 6:23am, 11 Feb, 2020

 https://www.scmp.com/news/china/society/article/3049931/coronavirus-hubei-province-reports-2097-new-cases-and-103-new 

 China / Society

• Remdesivir, developed by Gilead Sciences, was last week given to US patient whose condition appeared to improve within a day
• Tests are being carried out at multiple hospitals in Wuhan, ground zero of the outbreak

Phoebe Zhang

Published: 5:04pm, 3 Feb, 2020

 The experimental antiviral drug, Remdesivir, developed by US-based Gilead Sciences, is aimed at infectious diseases such Ebola and Sars. It was 

given to the first US patient

last week – a 35-year-old man whose condition appeared to improve within a day. 

 On Friday, The Wall Street Journal reported that Chinese officials had reached an agreement with Gilead (ticker: GILD) to test remdesivir in patients with coronavirus. The same day, the New England Journal of Medicine published a case report on a man sickened with the coronavirus in Washington state who was given remdesivir, and whose condition began to improve the following day. 

 https://www.barrons.com/articles/gilead-stock-coronavirus-treatment-experimental-aniviral-drug-remdesivir-tamiflu-51580739292 

ISSN 1748-7838 (online) 

• Letter to the Editor
• Open Access
• Published: 04 February 2020

• Manli Wang, 
• Ruiyuan Cao, 
• Leike Zhang, 
• Xinglou Yang, 
• Jia Liu, 
• Mingyue Xu, 
• Zhengli Shi, 
• Zhihong Hu, 
• Wu Zhong & 
• Gengfu Xiao 

Cell Research (2020)Cite this article

 https://www.nature.com/articles/s41422-020-0282-0 

 By The New York Times 

 https://www.nytimes.com/2020/02/03/world/asia/coronavirus-china.html 

• New cases in Hubei province, the epicentre of the outbreak, reach 2,345 for a total of 13,522
• Deaths in the province rose by 64 to 414, another record high

Robert Delaney

Published: 7:27am, 4 Feb, 2020

 https://www.scmp.com/news/china/society/article/3048815/coronavirus-china-death-toll-hits-425-new-cases-hubei-jump 

 Feb 04, 2020 10:45 AMPODCAST

By Tanner Brown 

 https://www.caixinglobal.com/2020-02-04/caixin-sinica-podcast-coronavirus-101511269.html 

 Feb 04, 2020 06:41 PMPODCAST

 https://www.caixinglobal.com/2020-02-04/caixin-china-biz-roundup-new-coronavirus-recovery-rates-begin-outstripping-fatalities-101511487.html 

 China / Society

• China also registers another 3,971 confirmed cases, raising total to 24,324
• Majority of the new cases are in Hubei province

Owen Churchill

Published: 6:31am, 5 Feb, 2020

 https://www.scmp.com/news/china/society/article/3049011/coronavirus-death-toll-jumps-65-479-chinas-hubei-province 

 Feb 05, 2020 07:43 AMSOCIETY & CULTURE

By Wen Simin, Gao Yu, Zhao Jinzhao and Han Wei 

 https://www.caixinglobal.com/2020-02-05/hong-kongs-1st-coronavirus-fatality-is-39-year-old-man-101511593.html 

 A lethal new virus that originated in the central China city of Wuhan has spread to the rest of the country and is fast infecting the world, creating one of the biggest global health crises since Ebola and SARS. Beijing has shut down huge swaths of the country and other nations are rapidly cutting travel links and taking other drastic measures that could send a chill through the global economy.

Editor: Lin Jinbing. Producer: Yu Zhuyangyang 

 https://www.caixinglobal.com/2020-02-03/coronavirus-latest-since-feb-1-confirmed-cases-14380-in-china-canada-starts-limited-evacuation-but-no-travel-ban-101510591.html 

Human trials of coronavirus drug begin

Chinese authorities have fast tracked a clinical trial by pharmaceutical giant Gilead of a drug to treat the novel coronavirus.

Antiviral drug remdesivir, a failed Ebola treatment, will be tested by a medical team from Beijing's China-Japan Friendship Hospital to treat coronavirus patients, Bloomberg reported, as well as in Wuhan. In all, 270 patients will participate in the randomized double-blinded placebo controlled study. Gilead rival AbbVie's HIV medicine Kaletra has also been recommended by China's health regulator for ad-hoc treatment of the new virus, for which there is as yet no approved drug treatment.

Full development and commercialization of a coronavirus vaccine could be years away.

 Healthcare 

Feb. 5, 2020 11:24 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor  

 Chinese authorities have OK'd the start of clinical trials. 

 https://seekingalpha.com/news/3538631-testing-of-gileads-remdesivir-in-coronavirus-patients-to-start-tomorrow-in-china?v=1580927483 

Tue February 4, 2020 9:00 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y., Feb. 4, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) 

 https://newsroom.regeneron.com/news-releases/news-release-details/palm-ebola-clinical-trial-stopped-early-regenerons-regn-eb3 

 https://www.regeneron.com/pipeline 

 https://www.prnewswire.com/news-releases/regeneron-announces-expanded-collaboration-with-hhs-to-develop-antibody-treatments-for-new-coronavirus-300998140.html 

 Regeneron's proprietary VelociSuite® technologies – including the VelocImmune® platform which uses a unique genetically-engineered mouse with a humanized immune system 

 https://www.regeneron.com/technology 

 REGN-EB3 (also known as REGN3470-3471-3479) was invented by Regeneron using its VelociSuite® technologies; the therapy combines three fully-human monoclonal antibodies. 

 "REGN-EB3 is a three-antibody cocktail designed with the goal of enhancing efficacy, reducing the development of viral sequences that lead to resistance, and increasing potential utility in future outbreaks as viruses continually evolve," said Christos Kyratsous, Ph.D., Vice President of Research, Infectious Diseases and Viral Vector Technologies at Regeneron. "The Regeneron rapid response infectious disease platform has the opportunity to accelerate our response to future epidemics and pandemics, and we continue to work on additional diseases that may pose a threat to public health." 

 https://newsroom.regeneron.com/news-releases/news-release-details/palm-ebola-clinical-trial-stopped-early-regenerons-regn-eb3 

 https://www.regeneron.com/technology 

 Feb 04, 2020 08:30 PMSOCIETY & CULTURE

 https://www.caixinglobal.com/2020-02-04/coronavirus-latest-since-feb-1-confirmed-cases-14380-in-china-canada-starts-limited-evacuation-but-no-travel-ban-101510591.html 

• Arbidol, an antiviral drug used for treating influenza in China and Russia, could be combined with the anti-HIV drug Darunavir for treating coronavirus
• Hospitals in Bangkok, and the Zhejiang provincial capital of Hangzhou, are reporting successes in reducing viral loads with ‘cocktail therapies’

Eric Ng

Published: 2:24pm, 4 Feb, 2020

 https://www.scmp.com/business/companies/article/3048888/could-cocktail-therapies-hiv-and-flu-be-magic-cure-new

 https://www.cochranelibrary.com/es/cdsr/doi/10.1002/14651858.CD011489/full/es 

 https://www.cochranelibrary.com/es/ 

Arbidol, an antiviral drug used for treating influenza in Russia and China, could be combined with the anti-HIV drug Darunavir for treating patients afflicted with the novel coronavirus, according to China Business News, citing a proposal on Tuesday by China’s National Health Commission expert Li Lanjuan.

In Thailand, a combination of anti-influenza medication Oseltamivir and HIV drugs Lopinavir and Ritonavir have been used on three patients with severe symptoms, according to Thai media reports, citing the Rajavithi Hospital’s director Somkiat Lalitwongsa in Bangkok. One of the patients, a 71-year-old woman, showed signs of improvement 48 hours after being administered the cocktail of drugs, the reports said.

China coverage from Reuters.

 https://www.reuters.com/places/china 

By CAO YIN | chinadaily.com.cn | Updated: 2020-02-03 09:05 

 https://www.chinadaily.com.cn/a/202002/03/WS5e3771e1a310128217274451.html  

By Liu Zhihua | China Daily | Updated: 2020-02-04 08:48 

 https://www.chinadaily.com.cn/a/202002/04/WS5e38bf5fa31012821727498a.html 

病毒：新型冠状病毒 2019-nCoV

传染源：新型冠状病毒感染的肺炎患者

传播途径：经呼吸道飞沫传播，亦可通过接触传播，存在粪-口传播可能性

 截至 2020-02-04 09:48 全国数据统计

 疑似病例数来自国家卫健委数据，目前为全国数据，未分省市自治区等
 

 http://ncov.dxy.cn/ncovh5/view/pneumonia?scene=2&clicktime=1579582238&enterid=1579582238&from=singlemessage&isappinstalled=0 

Virus: New Coronavirus 2019-nCoV

Source of infection: New coronavirus-infected pneumonia patients

Transmission: It can be transmitted through respiratory droplets or through contact. There is a possibility of fecal-oral transmission

 As of 2020-02-04 10:36 National Statistics
  The number of suspected cases comes from the data of the National Health and Health Commission, which is currently national data, not divided into provinces, municipalities and autonomous regions http://ncov.dxy.cn/ncovh5/view/pneumonia?scene=2&clicktime=1579582238&enterid=1579582238&from=singlemessage&isappinstalled=0 

ISSN 1748-7838 (online) 

• Letter to the Editor
• Open Access
• Published: 04 February 2020

• Manli Wang, 
• Ruiyuan Cao, 
• Leike Zhang, 
• Xinglou Yang, 
• Jia Liu, 
• Mingyue Xu, 
• Zhengli Shi, 
• Zhihong Hu, 
• Wu Zhong & 
• Gengfu Xiao 

Cell Research (2020)Cite this article

 https://www.nature.com/articles/s41422-020-0282-0 

 Recently, the Wuhan Institute of Virology, Chinese Academy of Sciences / National Institute of Biosafety and the National Academy of Military Medical Research Institute of Emergency Medicine for Prevention and Control of Drugs have jointly conducted research on the screening of 2019 new coronavirus ( 2019-nCoV ) drugs Important progress. Relevant research results to "Remdesivir and chloroquine Effectively INHIBIT at The Recently Logs in emerged Novel coronavirus (2019-nCoV) in vitro " ( "Reed Western Wei and chloroquine phosphate can inhibit the in vitro novel coronavirus ( 2019-nCoV )") was published In Cell Research, a well-known international academic journal with independent intellectual property rights in China . 

 http://www.whiov.cas.cn/kyjz_105338/202002/t20200204_5497136.html 

 近日，中国科学院武汉病毒研究所/生物安全大科学研究中心与军事科学院军事医学研究院国家应急防控药物工程技术研究中心开展联合研究，在抑制2019新型冠状病毒（2019-nCoV）药物筛选方面取得重要进展。相关研究成果以“Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”（《瑞得西韦和磷酸氯喹能在体外有效抑制新型冠状病毒（2019-nCoV）》）为题发表在中国自主知识产权的国际知名学术期刊Cell Research（《细胞研究》）上。 

 http://www.whiov.cas.cn/kyjz_105338/202002/t20200204_5497136.html 

 (1/31/19 2019-nCoV Global Confirmed Cases - John Hopkins University) 

 https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 

  Coronavirus 

Source: China's NHC, state media, other authorities

SCMP

 https://multimedia.scmp.com/widgets/china/wuhanvirus/# 

 WUHAN CORONAVIRUS OUTBREAK 

 https://www.worldometers.info/coronavirus/ 

 病毒: 新型冠状病毒 2019-nCoV  

Virus: New Coronavirus 2019-nCoV

 sources used By Johns Hopkins Database
CDC, WHO, NHC. ECDC and DXY 

 http://ncov.dxy.cn/ncovh5/view/pneumonia?scene=2&clicktime=1579582238&enterid=1579582238&from=singlemessage&isappinstalled=0 

 https://www.the-scientist.com/news-opinion/where-coronaviruses-come-from-67011 

 China / Society

• People showing pneumonia symptoms, and those who have had close contact with confirmed cases, will be given free accommodation and medical treatment in centralised zones
• First overseas fatalities reported in the Philippines as death toll rises to 305, with more than 14,500 confirmed cases

Cissy Zhou

Published: 6:42am, 2 Feb, 2020

 HEALTH NEWSFEBRUARY 2, 2020 / 8:01 AM / UPDATED 5 HOURS AGO

Panu Wongcha-um

BANGKOK (Reuters)

 The drug treatment includes a mixture of anti-HIV drugs lopinavir and ritonavir, in combination with flu drug oseltamivir in large doses. 

 https://www.reuters.com/article/us-china-health-thailand/cocktail-of-flu-hiv-drugs-appears-to-help-fight-coronavirus-thai-doctors-idUSKBN1ZW0GQ 

 lopinavir and ritonavir =
www.kaletra.com/... ($ABBV)
oseltamivir (Tamiflu) =
https://www.tamiflu.com/ ($RHHBY) 

FRENCH PRESS AGENCY - AFPBANGKOKPublished02.02.202021:15 

 https://www.dailysabah.com/health/2020/02/02/thailand-cures-coronavirus-with-anti-hiv-drug-cocktail-in-48-hours 

 Asia / Southeast Asia

• The victim was a 44-year-old male Chinese national who was the companion of a 38-year-old Chinese woman who arrived in the Philippines on January 21
• A new Philippine travel ban could apply to all travellers from China, including Hong Kong

Compiled by SCMP’s Asia desk,Sum Lok-kei,Phila Siu

Published: 9:51am, 2 Feb, 2020

 Feb 03, 2020 04:58 AM SOCIETY & CULTURE

By Gao Yu, Xiao Hui, Ma Danmeng, Cui Xiankang and Han Wei 

 https://www.caixinglobal.com/2020-02-03/in-depth-how-wuhan-lost-the-fight-to-contain-the-coronavirus-101510749.html 

CORRESPONDENCE

 January 30, 2020
DOI: 10.1056/NEJMc2001468
Metrics This letter was published on January 30, 2020, at NEJM.org.  

 This letter was published on January 28, 2020, at NEJM.org. 

 https://www.nejm.org/doi/full/10.1056/NEJMc2001272?query=RP 

 RESEARCH ARTICLE 

 mbio.asm.org 

 March/April 2018 Volume 9 Issue 2 e00221-18 

 Coronavirus Susceptibility to the Antiviral Remdesivir (GS5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease 

 Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA 

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA 

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA 

Department of Biology, the University of the South, Sewanee, Tennessee, USA

 Gilead Sciences, Inc., Foster City, California, USA 

 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844999/pdf/mBio.00221-18.pdf 

chinadaily.com.cn | Updated: 2020-02-02 07:55

 About China Daily 

 https://www.chinadaily.com.cn/index.html 

By Zhong Nan | chinadaily.com.cn | Updated: 2020-02-02 10:01 

 https://www.chinadaily.com.cn/a/202002/02/WS5e362d5ca310128217274260.html 

  THE JAKARTA POST 

MARIE-MORGANE LE MOEL

AGENCE FRANCE-PRESSE

Paris  /  Sat, February 1, 2020  /  10:15 am 

Moderna is working in coordination with the US National Institutes of Health, while Inovio Pharmaceuticals and the University of Queensland in Australia are pursuing alternative tracks. (Shutterstock/Parilov)

 Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus   

 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 23, 2020-- Moderna, Inc., (Nasdaq: MRNA) 

 https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-funding-award-cepi-accelerate-development 

Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat

Initiating Vaccine Development and Providing Supplies of Antiviral Medicines to China for Investigational Use

 NEW BRUNSWICK, N.J., January 29, 2020 

 https://www.jnj.com/johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat  THE JAKARTA POST 

PUBLISHED FRI, JAN 31 20202:31 PM ESTUPDATED FRI, JAN 31 20203:18 PM ESTBerkeley Lovelace Jr.@BERKELEYJR
https://www.cnbc.com/2020/01/31/coronavirus-why-it-takes-at-least-a-year-to-make-a-vaccine.html 

Ashish Joshi

Health correspondent @ashishskynews

Wednesday 5 February 2020 19:50, UK

  https://news.sky.com/story/coronavirus-significant-breakthrough-in-race-for-vaccine-made-by-uk-scientists-11926469 

An outbreak of novel coronavirus (2019-nCoV) that began in Wuhan, China, has spread rapidly, with cases now confirmed in multiple countries. We report the first case of 2019-nCoV infection confirmed in the United States and describe the identification, diagnosis, clinical course, and management of the case, including the patient’s initial mild symptoms at presentation with progression to pneumonia on day 9 of illness. This case highlights the importance of close coordination between clinicians and public health authorities at the local, state, and federal levels, as well as the need for rapid dissemination of clinical information related to the care of patients with this emerging infection.

 Copyright © 2020 Massachusetts Medical Society 

 Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. 

December 10, 2019

 https://www.nih.gov/news-events/nih-research-matters/two-drugs-reduce-risk-death-ebola?mod=article_inline 

 https://news.abbvie.com/news/media-statements/abbvie-statement-on-coronavirus-and-lopinavirritonavir.htm 

KALETRA is a prescription medicine that is used with other antiretroviral medicines to treat human immunodeficiency virus-1 (HIV-1) infection in adults and children 14 days of age and older. HIV is the virus that causes AIDS (acquired immune deficiency syndrome). It is not known if KALETRA is safe and effective in children under 14 days old.

 https://www.kaletra.com/?cid=ppc_ppd_kaletra_ggl_br_0140 

 Jan 29, 2020 08:56 PMSOCIETY & CULTURE

By Guo Yingzhe 

Summary

A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. 

 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext 

 2019 新型冠状病毒疫情进展和风险评估 Epidemic update and risk assessment of 2019 Novel Coronavirus     中国疾病预防控制中心新型冠状病毒感染的肺炎疫情一级响应 态势分析与风险评估组 2020 年 1 月 28 日  

 http://www.chinacdc.cn/yyrdgz/202001/P020200128523354919292.pdf 

ABC Health & Wellbeing

By Tegan Taylor

Updated Saturday at 23:51First posted 20 January 2020 at 12:55 am 

 https://www.abc.net.au/news/health/2020-01-20/coronavirus-chinese-pneumonia-mystery-explainer/11882490?pfmredir=ms 

 Published:January 30, 2020 

 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext 

In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)

 2019-nCoV Global Cases by Johns Hopkins CSSE 

 https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 

 The CDC is closely monitoring an outbreak of respiratory illness caused by a novel (new) coronavirus first identified in Wuhan, Hubei Province, China. Infections with 2019-nCoV also are being reported in a growing number of countries internationally, including the United States. There are ongoing investigations to learn more. 

 https://www.cdc.gov/media/dpk/diseases-and-conditions/coronavirus/coronavirus-2020.html 

 http://virological.org/t/novel-2019-coronavirus-genome/319 

 Feb 01, 2020 10:42 PMSOCIETY & CULTURE

By Flynn Murphy, Lin Jinbing, Han Wei, Dave Yin, Matthew Walsh, Denise Jia, Mo Yelin and Timmy Shen 

 Feb 01, 2020 10:18 PMFINANCE

By Guo Yingzhe 

 https://www.caixinglobal.com/2020-02-01/chinas-central-bank-offers-more-aid-amid-virus-fallout-101510466.html 

 People’s Daily published (link in Chinese) a story hours later asking for caution and discouraging panic buying. 

 https://www.weibo.com/2803301701/Is8xy5pp0?from=page_1002062803301701_profile&wvr=6&mod=weibotime&type=comment#_rnd1580582282232 

 The New England Journal of Medicine, a U.S. medical journal, published a study Friday on the first coronavirus infection in the U.S. The case highlights an experimental drug remdesivir developed by Gilead Sciences Inc. It was given to the first U.S. case whose clinical condition improved the next day, the study showed. The report also stressed the importance of close coordination between clinicians and public health authorities at all levels of government, as well as the need for rapid dissemination of clinical information related to the care of patients with this emerging infection. 

 https://www.nejm.org/doi/full/10.1056/NEJMoa2001191 

Jan. 23, 2020, 1:35 PM; Updated: Jan. 23, 2020, 2:06 PM 

 https://news.bloomberglaw.com/pharma-and-life-sciences/gilead-assesses-ebola-drug-as-possible-coronavirus-treatment 

 Remdesivir is an experimental antiviral drug that grew out of a collaboration with the Centers for Disease Control and Prevention and the U.S. Army Medical Research Institute of Infectious Diseases in 2014. It works by blocking a key enzyme the virus needs for replication, the company explained in a statement.  

 https://www.gilead.com/purpose/advancing-global-health 

 Xinhua News Agency, China’s state run press agency, is reporting nearly 600 cases of pneumonia linked to the new strain of coronavirus in an outbreak that began last month in Wuhan City in China. That’s almost double the number of cases the World Health Organization had reported on Jan. 21 

 Novel Coronavirus (2019-nCoV) SITUATION REPORT - 1 21 JANUARY 2020 

 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf 

 Remdesivir (GS-5734) 

 https://stm.sciencemag.org/content/11/494/eaau9242.full 

Feb. 1, 2020 1:25 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor 

In a statement, Gilead Sciences (NASDAQ:GILD)

 https://seekingalpha.com/news/3537087-gilead-advancing-experimental-antiviral-to-treat-coronavirus-infection 

 China

• Findings by scientists at Hong Kong University based on the assumption that each infected patient could have infected 2.68 others
• Meanwhile, numbers of new infections and deaths set daily records

Cissy Zhou,Josephine Ma,Stephen Chen in Beijing,Phoebe Zhang

Published: 8:17am, 1 Feb, 2020

 World / United States & Canada

• Foreign nationals arriving in the US from mainland China will be denied entry starting Sunday
• US citizens who have been in Hubei province will be quarantined for two weeks

Bhavan Jaipragas

Published: 5:23am, 1 Feb, 2020

 https://www.scmp.com/news/world/united-states-canada/article/3048510/coronavirus-us-declares-public-health-emergency 

Source: China's NHC, state media, other authorities

SCMP

 https://multimedia.scmp.com/widgets/china/wuhanvirus/# 

 Feb 01, 2020 08:40 PMSOCIETY & CULTURE

By Lu Yutong, Ye Xueming, Wang Xintong and Flynn Murphy

Some 40 airlines in 29 countries and regions have suspended flights to the Chinese mainland amid fears about the deadly coronavirus that has infected thousands and killed hundreds.

 https://www.caixinglobal.com/2020-02-01/airlines-cut-flights-and-routes-to-china-as-virus-fears-grow-101510422.html 

Foster City, Calif., January 31, 2020 — Gilead Sciences today issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences:

  Remdesivir (GS-5734)  

 https://www.gilead.com/purpose/advancing-global-health 

by Nick Paul Taylor | Jan 24, 2020 8:22am 

 https://www.fiercebiotech.com/biotech/gilead-mulls-repositioning-failed-ebola-drug-china-virus 

December 10, 2019

 https://www.nih.gov/news-events/nih-research-matters/two-drugs-reduce-risk-death-ebola?mod=article_inline 

 https://www.wsj.com/articles/gilead-sciences-offers-experimental-drug-for-coronavirus-treatments-testing-11580511519 

 By Joseph Walker

• BIOGRAPHY
• @JOEWALKERWSJ
• JOSEPH.WALKER@WSJ.COM

Updated Jan. 31, 2020 8:33 pm ET 

Gilead Sciences Inc. GILD -1.30% 

 https://www.wsj.com/articles/u-s-drugmakers-ship-therapies-to-china-seeking-to-treat-coronavirus-11580166592?mod=article_inline 

 NEWS > SPOKANE

UPDATED: Fri., Jan. 31, 2020

 https://www.spokesman.com/stories/2020/jan/31/washington-state-coronavirus-patient-treated-with-/ 

  By Arielle Dreher arielled@spokesman.com (509)459-5467 

Published: 10 January 2020

remdesivir and combination lopinavir, ritonavir, and interferon 

 https://www.nature.com/articles/s41467-019-13940-6 

Dec. 24, 2019 6:27 AM ET

Summary

this has been the “Biotech Decade” 2010-2019.

this year has been the “Biotech Year”.

Based on the current political environment it has been a spectacular year for the healthcare sector, and for many biotech companies.

  |About: AbbVie Inc. (ABBV), ABMD, ABT, AMGN, AMRN, AZN, BGNE, BIIB, BLUE, BMRN, BMY, GILD, ISRG, JNJ, LLY, MDT, MRK, NVS, PFE, REGN, RHHBY, SGEN, SRPT, VRTX  

 Dec. 15, 2019 4:18 PM ET|

Summary

the biotech sector is essentially avoided, at least publicly, as a recommended investment sector.

the 2020 political BiotechSTORM is coming.

I guess that If you can’t get anyone on TV to make positive comments on biotech companies then the sector must not be well liked or a good investment?

I guess the biotech/medtech successes for the past 10 years are and will remain a secret success story and a bewildering anomaly?

There has been “Nothing Else” but biotech success stories this December 2019 as there have been the entire year of 2019. 

This has been the BIOTECH DECADE -2010-2019.

Dec. 15, 2019 4:18 PM ET|About: AbbVie Inc. (ABBV), ABMD, AMGN, AMRN, AZN, BIIB, BLUE, BMY, CELG, GILD, IBB,  

Dec. 31, 2019 4:20 PM ET 

 Summary

this has been the BIOTECH Decade.

10 years of phenomenal clinical success stories in many areas and that is “All That Matters".

And this year 2019 has been a great year for the entire biotech sector.

  AbbVie Inc. (ABBV), ABMD, ABT, AMGN, AMRN, AZN, BGNE, BIIB, BLUE, BMRN, BMY, GILD, ISRG, JNJ, LLY, MDT, MRK, NVS, PFE, REGN, RHHBY, SGEN, SRPT, VRTX  

Summary

politicos have made a massive mistake vilifying the biotech sector.

politicos continue to see the biotech sector as easy targets in an effort to gain votes and win elections.

It is time for all biotech companies to take counteroffensive measures.

  In a year that the biotech sector has been totally maligned by politicos, biotech companies will again achieve outstanding medical success as they did in 2018. I remain 100% invested in biotech and medtech companies as of 9/18/2019. And I remain long (JNJ).   

Summary

candidates now see political socialism as the “morally” correct mandate,

a significant block of voters seem to want much more and expect much more from their government.

Nevertheless, and while under attack, biotech companies continue to bring successful products to market.

  I am re-investing my biotech dividends back into additional shares of the following companies; (PFE), (JNJ), (LLY), (MRK), (AMGN), (BMY), (AZN), (ABBV), (MDT), (CELG), (GILD), (NVS), (OTCQX:RHHBY)   

. 

Merck Foundation Launches Five-Year Initiative to Reduce Disparities in HIV Care for Vulnerable and Underserved Southeastern US Communities.

Janssen Announces U.S. FDA Breakthrough Therapy Designation for Investigational Prophylactic Vaccine for the Prevention of Respiratory Syncytial Virus in Older Adults Leiden, The Netherlands, September 3, 2019 –.

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC).

Dec. 9, 2019 8:35 AM ET|About: AbbVie Inc. (ABBV), ALPMY, BMY, CELG, JNJ, MRK, PFE, RHHBY, SGEN

Summary

There is no impossible.

2019, has been a breakthrough year for all who need medicine.

many clinical tests involving combinations of successful medicines.

many approvals this year in China for successful medicines.

Dec. 4, 2019 2:20 PM ET|About: Alphabet Inc. (GOOGL), Includes: BMY, JNJ, MRK, PFE, RHHBY, SGEN

Summary

politicos miss the real underlying support for the companies in the biotech/drug sector = medicine that brings about positive and encouraging outcomes, medicine that brings about successful outcomes.

The biotech/medtech success stories for all of November & early December 2019 are remarkable.

But it is not just the biotech sector that is under attack, big USA tech companies remain targets.

Nov. 23, 2019 8:40 PM ET|About: Bristol-Myers Squibb Company (BMY), CELG, Includes: AMRN, JNJ, MRK, NVO, NVS, PFE, RHHBY

Summary

For me the world is upside down when success and profit and shareholders and new medicines and new medical devises and new products are vilified, this is insanity.

New Jersey is the “Biotech State”.

Unfortunately, the Biotech-War$™ continue in November 2019 and continue to expand at a high speed towards encompassing many other WAR$ against new business sectors.

But please don’t tell any Politicos about these biotech victories below they would not understand these remarkable events – just read them At Your Whisper, shhh….

“Let’s show them we are better”.

Nov. 14, 2019 9:50 PM ET|About: Amarin Corporation plc (AMRN), BMY, MRK, PFE

Summary

“POLITICAL ZOMBIES” and are now fully targeting ALPHA.

Zombies create “Irrational FEAR”, they thrive on “Irrational FEAR”

.

HOPE is a mechanism developed by the human brain to cope with contexts and situations unfavorable to survival.

HOPEFUL news events, many are even remarkable, in the Biotech and MedTech sectors in just the first 14 days of November 2019 and they WON'T STOP NOW.

Nov. 9, 2019 6:45 PM ET|About: AbbVie Inc. (ABBV), ABMD, ABT, AGN, AMGN, AMRN, AZN, BGNE, BIIB, BMRN, BMY, CELG, GILD, ILMN, ISRG, JNJ, LLY, MDT, MRK, NVO, NVS, PFE, REGN, RHHBY, SGEN, VAR, VRTX

Summary

Politicos are now simultaneously spearheading Biotech-WAR$™, Tech WARS, and now Class WARS.

The biotech/medtech sectors continue to succeed and are on track to have another banner 2019 both in product development and financial success.

Billionaire Leon Cooperman has had enough and is fighting back.

Google and Facebook and Twitter should all fight back as should every Biotech company, every Bank, every business in the America.

Oct. 14, 2019 2:38 PM ET|About: Amgen Inc. (AMGN), AZN, BMY, GILD, JNJ, LLY, MRK, PFE, RHHBY, SGEN, MDT

Summary

I see the power of many “Biotech Victory's”. every day.

promote the power of a “Biotech Victory”.

politicos have made a grave mistake vilifying the biotech sector.

 Feb. 20, 2019 11:04 PM ET|Includes: AbbVie Inc. (ABBV), ABT, ALKS, AMGN, CELG, CERC, CLVS, JNJ, LLY, MDT, MRK, NVO, PFE

Summary

A BIOTECH VORTEX™ is occurring across the entire healthcare sector as companies are now Seeking Biotech Partnerships to gain momentum.

Biotech & Biotech Partnerships.

Biotech & Medtech Partnerships.

Biotech & Medtech & Medical Universities Partnerships.

Biotech & Health Systems Partnerships.

  Mar. 6, 2019 8:12 AM ET|Includes: AbbVie Inc. (ABBV), AMGN, AZN, BMY, CELG, JNJ, LLY, MRK, PFE, SRPT

Summary

Sometimes biotech news is wonderful news.

Sometimes biotech news is the best and most upbeat news I read all day.

Sometimes with great effort and much time and money spent biotech news is remarkable news for many people seeking solutions to specific medical conditions and aliments.

The first 2 months of 2019 have been extremely strong for many of my biotech positions.

Nov. 2, 2019 8:29 AM ET|2 comments |About: Amgen Inc. (AMGN), BGNE, BMY, GILD, PFE, SGEN, VRTX, VAR, NVO

Summary

The progress and product successes being achieved in the Biotech sector this September and October 2019 is nothing less than remarkable.

remarkable Biotech/MedTech gains in September 2019 and October 2019.

In the Hebrew Bible hôšîʿâ-nā is used only in verses such as "help" or "save, I pray" (Psalms 118:25).

 In the Hebrew Bible hôšîʿâ-nā is used only in verses such as "help" or "save, I pray" (Psalms 118:25). 

Oct. 18, 2019 12:50 PM ET|About: AbbVie Inc. (ABBV), AMGN, JNJ, LLY, MRK, VRTX, Includes: AMRNSummary

Are successful USA based companies now the “enemy of the state”?

Cambridge, Mass. is in my view the epicenter of the biotech industry.

The attacks on all biotech companies will only benefit biotech hubs in Shanghai, China, Basel, Switzerland and Dublin, Ireland all highly supportive biotech centers.

  Apr. 2, 2019 8:20 PM ET|About: AstraZeneca PLC (AZN), BMY, CELG, Includes: AMRN, JNJ, MRK, NVO, NVS, PFE, RHHBY, SNY

Summary

“TINSTAAFL” = “There is no such thing as a free lunch”.

Princeton NJ/Central Jersey – is for me the best example of a successful BioTECH Zone.

Ireland's Life Sciences sector has grown from very humble beginnings in the 1960s to reach global significance. Collaborative clusters in Pharmaceutical, Biotechnology, Medical Devices and Diagnostics have been a key.

AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi, China, that aims to nurture innovation.

Cambridge, Mass, is one of the best examples of a successful BioTECH Zone.

 Mar. 14, 2018 1:14 PM ET|About: Amgen Inc. (AMGN), AZN, BGNE, CELG, NVS, Includes: ABMD, BMY, LLY, MDT, MRK, NVO

Summary

China Bio-Tech growth is accelerating now.

China needs better healthcare in every province.

China will welcome all bio-technology partnerships.

China is on the verge of major investment changes.

Lilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes

Wed June 26, 2019 6:45 AM|PR Newswire|About: LLY

INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) 

 https://www.lillydiabetes.com/ 

 FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis

Wed June 26, 2019 1:29 PM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and PARIS, June 26, 2019 /PRNewswire/ --

 https://www.prnewswire.com/news-releases/fda-approves-dupixent-dupilumab-for-chronic-rhinosinusitis-with-nasal-polyposis-300875536.html 

 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript)

Jun. 25, 2019 3:28 PM ET|83 comments  | About: AbbVie Inc. (ABBV) 

 U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Wed June 26, 2019 6:00 AM|PR Newswire|About: LLY

• - FDA's Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 6.5 million people in the U.S. who have heart failure

PR Newswire

RIDGEFIELD, Conn. and INDIANAPOLIS, June 26, 2019 /PRNewswire/

 https://www.prnewswire.com/news-releases/us-fda-grants-fast-track-designation-to-empagliflozin-for-the-treatment-of-chronic-heart-failure-300874752.html 

 Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket

Tue June 25, 2019 4:00 PM|PR Newswire|About: AMGNPR Newswire

SAN FRANCISCO, June 25, 2019 /PRNewswire/ -- Amgen  (AMGN) and MBC BioLabs (formerly QB3@953) 

 https://www.prnewswire.com/news-releases/amgen-and-mbc-biolabs-announce-winners-of-the-amgen-golden-ticket-300874554.html 

  German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma

Wed June 26, 2019 7:30 AM|Business Wire|About: NVCR

National reimbursement decision for Optune® in Germany anticipated in 2020

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NVCR) 

 please visit www.novocure.com or follow us at www.twitter.com/novocure. 

U.S. FDA Accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)

Thu June 20, 2019 8:15 AM|Business Wire|About: ALXN

- FDA sets target action date of October 19, 2019 -

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (ALXN) 

BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML)

Thu June 20, 2019 11:05 AM|GlobeNewswire|About: BGNE

CAMBRIDGE, Mass. and BEIJING, China, June 20, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

 https://www.gazyva.com/ 

 Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma

Fri June 21, 2019 12:59 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and PARIS, June 21, 2019 /PRNewswire/ -- 

REGN3500 monotherapy significantly reduced loss of asthma control and improved lung function compared to placebo

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi

 Janssen Announces Collaboration with University of California, Berkeley and University of California, San Francisco to Expand Data Science Research in Healthcare

Thu June 20, 2019 9:00 AM|Business Wire|About: JNJ

The program facilitated by Johnson & Johnson Innovation will recruit data scientists to research high impact, data-science projects in healthcare

SAN FRANCISCO--(BUSINESS WIRE)-- Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ)   

 https://www.businesswire.com/news/home/20190620005351/en/ 

QIAGEN Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed and Interpreted

Thu June 20, 2019 10:00 AM|Business Wire|About: QGEN

Industry-leading bioinformatics software delivers genomic insights for precision medicine

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA)

 https://www.businesswire.com/news/home/20190620005371/en/ 

Editas Medicine (EDIT) Investor Presentation - Slideshow

Jun. 20, 2019 12:07 PM ET|2 comments | About: Editas Medicine, Inc. (EDIT) 

 Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis

Mon June 17, 2019 8:30 AM|PR Newswire|About: ARNA

• - ELEVATE UC clinical trial sites continue to initiate

PR Newswire

SAN DIEGO, June 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) (Nasdaq: ARNA)

 Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Tue June 18, 2019 4:05 PM|Business Wire|About: AGN, IRWD 

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

• Thu June 13, 2019 7:13 PM|PR Newswire|About: AGN, AMGN
• Third FDA Approval From Amgen's Biosimilars Portfolio

PR Newswire

THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (AMGN) and Allergan plc (AGN)

 BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

Tue June 18, 2019 7:00 AM|GlobeNewswire|About: BGNE

CAMBRIDGE, Mass. and BEIJING, China and STAMFORD, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

 Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

Wed June 19, 2019 8:30 AM|GlobeNewswire|About: GILDGlobeNewswire

FOSTER CITY, Calif. and SAN FRANCISCO, June 19, 2019 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc

 Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership

Wed June 19, 2019 4:00 PM|PR Newswire|About: AMGNPR Newswire

THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ -- Amgen (AMGN) and the University of Washington's Institute for Protein Design (IPD)

 https://www.prnewswire.com/news-releases/amgen-and-the-institute-for-protein-design-ipd-at-university-of-washington-announce-unique-strategic-research-partnership-300871544.html 

Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial

Wed June 19, 2019 7:00 AM|GlobeNewswire|About: SRNE 

 Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

Fri June 14, 2019 7:00 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y., June 14, 2019 /PRNewswire/ 

 MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis

Fri June 14, 2019 8:20 AM|Accesswire|About: JNJ, MOR, MPSYY

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 14, 2019 / MorphoSys AG (MPSYF) (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) 

 Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States

Wed June 19, 2019 7:00 AM|PR Newswire|About: BHC

New Lens is the Most Advanced Soft Contact Lens Design in Bausch + Lomb History

Only Multifocal Toric Lens that Offers Eye Care Professionals a Convenient Same-Day Fit to Address Patients with Astigmatism and Presbyopia

BRIDGEWATER, N.J., June 19, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (BHC)

 AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer

Wed June 19, 2019 6:45 AM|Business Wire|About: MRK

LYNPARZA is the Only PARP Inhibitor Approved in Japan

KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (MRK)

Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology

Fri June 14, 2019 3:24 PM|Canada Newswire|About: LLY

TORONTO, June 14, 2019 /CNW/ - Eli Lilly and Company (LLY)

AstraZeneca's Lokelma helped improve potassium levels in dialysis patients

Jun. 14, 2019 8:09 AM ET|About: AstraZeneca PLC (AZN)|By: Liz Kiesche, SA News Edito 

 New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients

Thu June 13, 2019 4:30 PM|Business Wire|About: BMY 

CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory  

Chronic Lymphocytic Leukemia

Sat June 15, 2019 7:00 AM|Business Wire|About: AZN

An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine

WILMINGTON, Del.--(BUSINESS WIRE)--

Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019

• Sun June 16, 2019 2:00 AM|PR Newswire|About: AMGN
• More Than Half of Patients who Achieved an MRD-Negative Complete Response Still Alive at Five Years
• Only CD19-Targeted Immuno-oncology Therapy With Five-Year Survival Data

PR Newswire

THOUSAND OAKS, Calif., June 15, 2019 /PRNewswire/ -- Amgen (AMGN) 

 ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Tue June 18, 2019 6:30 AM|Business Wire|About: ALXN 

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy

Tue June 18, 2019 6:45 AM|Business Wire|About: MRK

Marks First Approval for KEYTRUDA in SCLC

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)